Dendreon Corp. (DNDN). The biotechnology company said it ended a development and supply agreement with GlaxoSmithKline LLC (GSK) on Dendreon's prostate cancer vaccine, citing delays and difficulties in achieving the commercial purpose of the deal.
Dendreon's stock has fallen from $42 to $10.30 in the last 30 days.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment